Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. All News
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/20
0.335 AUD   -1.47%
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about MAYNE PHARMA GROUP LIMITED
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
10/06MAYNE PHARMA : to Address US FDA Feedback on Generic Version of Birth Control Product
MT
10/06MAYNE PHARMA : 07/10/2021 Mayne Pharma provides FDA update on generic NUVARING
PU
10/06Mayne Pharma Provides US Food and Drug Administration Update on Generic NUVARING
CI
10/05MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
10/04MAYNE PHARMA : appoints new Director
PU
10/03Mayne Pharma Group Limited Appoints Carolyn Myers to the Board
CI
09/30MAYNE PHARMA : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
AQ
09/29MAYNE PHARMA : Adds generic absorica to us dermatology portfolio
AQ
09/28MAYNE PHARMA : Starts Distribution of Severe Acne Treatment Drug in US
MT
09/28MAYNE PHARMA : 29/09/2021 Mayne Pharma adds generic ABSORICA® to US portfolio
PU
09/28Mayne Pharma Enters into Private Label Supply and Distribution Agreement with Upsher-Sm..
CI
09/27MAYNE PHARMA : Notification regarding unquoted securities - MYX
PU
09/22MAYNE PHARMA : Fda approves lexetteo for adolescent plaque psoriasis
AQ
09/21MAYNE PHARMA : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
09/21U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque P..
CI
09/02MAYNE PHARMA : Change of Director's Interest Notice
PU
08/27MAYNE PHARMA : 2021 Full Year Media Release
PU
08/27MAYNE PHARMA : 2021 Full Year Investor Presentation
PU
08/27MAYNE PHARMA : Appendix 4E and Statutory Accounts
PU
08/27MAYNE PHARMA : Widens Net Loss in FY21 on Higher Impairments
MT
08/26MAYNE PHARMA : 27/08/2021 Mayne Pharma 2021 Full Year Results Media Release
PU
08/26Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 20..
CI
08/26MAYNE PHARMA : board renewal and new Chairman
PU
08/26Mayne Pharma Group Limited Announces Board Changes
CI
08/03MAYNE PHARMA : Class action proceeding
AQ
08/03MAYNE PHARMA : 03/08/2021 MYX - Class action proceeding
PU
08/03MAYNE PHARMA : Notification of cessation of securities - MYX
PU
08/02MAYNE PHARMA : Change of Director's Interest Notice
PU
06/22Estelle Oral Contraceptive Now Available In the United States
AQ
06/20MAYNE PHARMA : Adds New Products to Australian Dermatology Portfolio
MT
06/20MAYNE PHARMA : Oral Contraceptive Introduced in the US; Shares Fall 3%
MT
06/20MAYNE PHARMA : 21/06/2021 Mayne Pharma Expands Australian Dermatology Portfolio
PU
06/20MAYNE PHARMA : 21/06/2021 Nextstellis® Oral Contraceptive Now Available in the United Stat..
PU
06/20Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces Availability of Nex..
CI
05/28Mayne - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Published
AQ
05/27MAYNE PHARMA : Nextstellis receives fda marketing exclusivity and phase iii data published
AQ
05/26MAYNE PHARMA : 27/05/2021 Nextstellis® Receives FDA Marketing Exclusivity and Phase III Da..
PU
05/26Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receive..
CI
05/13MAYNE PHARMA : Appendix 2A and Notice under ASX Listing Rule 3.10A
PU
04/30Mayne Pharma Announces Results from Two Studies Showing New Efficacy Data Reinforces NE..
CI
04/16MAYNE PHARMA : 16/04/2021 u.s. fda approves nextstellis®, new oral contraceptive
PU
04/16MAYNE PHARMA : And mithra announce fda approval of new oral contraceptive nextstellis
AQ
04/16Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle
AQ
04/15MAYNE PHARMA : FDA Approves Mayne Pharma, Mithra Pharmaceuticals' New Drug Application for..
MT
04/15MAYNE PHARMA : 16/04/2021 FDA approval of novel oral contraceptive NEXTSTELLIS
PU
04/15Mayne Pharma Group Limited and Mithra Pharmaceuticals SA Receives FDA Approval of New O..
CI
03/08MAYNE PHARMA : 08/03/2021 New data on NEXTSTELLIS presented at ISSWSH conference
PU
03/06Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Com..
CI
03/04Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive
CI
02/25MAYNE PHARMA : 2021 Half Year Results Media Release
AQ
02/23MAYNE PHARMA : 24/02/2021 Mayne Pharma 2021 Half Year Results Media Release
PU
02/23Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31..
CI
01/06MAYNE PHARMA : Launches Pregnancy Prevention Tablets in US
MT
01/06MAYNE PHARMA : launches Microgestin 24 FE tablets in the US
PU
01/06MAYNE PHARMA : 07/01/2021 Mayne Pharma launches Microgestin® 24 Fe tablets in the United S..
PU
01/06Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States
CI
2020MAYNE PHARMA : Extends Three-Year Bullet Facility
MT
2020MAYNE PHARMA : 18/12/2020 Mayne Pharma successfully extends debt facility
PU
2020MAYNE PHARMA : successfully extends debt facility
PU
2020MAYNE PHARMA : 24/11/2020 2020 AGM Chairman's Address
PU
2020MAYNE PHARMA : 24/11/2020 2020 AGM CEO's Speech
PU
2020MAYNE PHARMA : 09/11/2020 Mayne Pharma Board Renewal
PU
2020MAYNE PHARMA : Board Renewal
PU
2020MAYNE PHARMA : New data on Mayne Pharma's TOLSURA presented at IDWeek 2020
AQ
2020MAYNE PHARMA : 26/10/2020 New data on Mayne Pharma's TOLSURA presented at IDWeek 2020
PU
2020Mayne Pharma Group Limited Announces New Clinical Data Presents on TOLSURA® (SUBA®-itra..
CI
2020MAYNE PHARMA : Lapse of rights and AGM Notice of Meeting clarification
PU
2020MAYNE PHARMA : 2020 Annual General Meeting
PU
2020MAYNE PHARMA : 2020 Corporate Governance Statement
PU
2020MAYNE PHARMA : Annual Report to shareholders
PU
2020Mithra Announces FDA update
AQ
2020MAYNE PHARMA : provides update on Women's Health pipeline
AQ
1  2  3  4  5Next
Upcoming event on MAYNE PHARMA GROUP LIMITED
11/23/21